Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Short-term Investments: 2015-2025

Historic Short-term Investments for CytomX Therapeutics (CTMX) over the last 10 years, with Sep 2025 value amounting to $109.4 million.

  • CytomX Therapeutics' Short-term Investments rose 42.11% to $109.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $109.4 million, marking a year-over-year increase of 42.11%. This contributed to the annual value of $62.6 million for FY2024, which is 60.23% down from last year.
  • As of Q3 2025, CytomX Therapeutics' Short-term Investments stood at $109.4 million, which was up 0.36% from $109.0 million recorded in Q2 2025.
  • In the past 5 years, CytomX Therapeutics' Short-term Investments registered a high of $168.1 million during Q3 2023, and its lowest value of $5,000 during Q3 2021.
  • In the last 3 years, CytomX Therapeutics' Short-term Investments had a median value of $109.4 million in 2025 and averaged $108.7 million.
  • As far as peak fluctuations go, CytomX Therapeutics' Short-term Investments slumped by 100.00% in 2021, and later spiked by 1,984,980.00% in 2022.
  • CytomX Therapeutics' Short-term Investments (Quarterly) stood at $99.7 million in 2021, then soared by 1,984,980.00% to $99.3 million in 2022, then spiked by 69.35% to $157.3 million in 2023, then plummeted by 60.23% to $62.6 million in 2024, then surged by 42.11% to $109.4 million in 2025.
  • Its Short-term Investments stands at $109.4 million for Q3 2025, versus $109.0 million for Q2 2025 and $32.3 million for Q1 2025.